Book ChapterDOI
Traditional Chinese Medicines as Possible Remedy Against SARS-CoV-2
Saqib Mahmood,Tariq Mahmood,Naeem Iqbal,Samina Sabir,Sadia Javed,Muhammad Zia-Ul-Haq +5 more
- pp 63-109
TLDR
Wang et al. as mentioned in this paper proposed to use traditional Chinese medicine (TCM) against SARS-CoV in the third edition of COVID-19 Treatment Guidelines (2020) published in January 2019.Abstract:
Keeping in view the pandemic situation and whose recommendations to search antiviral medicines, biologists, pathologists, and microbiologists started working on that Chinese government has recommended therapeutic application of traditional Chinese medicine (TCM) against COVID-19 in the third edition of COVID-19 Treatment Guidelines (2020) published in January From the day onward, hundreds of herbs have been practiced all over China This chapter has been planned to compile existing information for future utilization of TCM all over the world with better understanding and minimal chances of side effects For well understanding of TCM as reliable treatment (for COVID-19), it is aimed to pool data of TCM from its history of usage against other viruses and against related viruses of SARS-CoV, collection of the data regarding case studies with positive outcomes, detailed pool of knowledge about most practiced (approved/proposed) decoctions, frequently used components of these decoctions, their active ingredients, possible mechanism to inhibit viruses, similarity of SARS-CoV with SARS-CoV-2, and possibility to treat COVID-19 with antiviral drugs previously used against SARS-CoV Additional relevant meta-analyses have been reviewed that may guide about practical implementation of these TCM in the future round the globeread more
Citations
More filters
Investigation on mechanism and active components of Shufeng Jiedu Capsule in treatment of COVID-19 based on network pharmacology and molecular docking/ 基于网络药理学与分子对接方法的疏风解毒胶囊治疗新型冠状病毒肺炎(COVID-19)的作用机制与活性成分研究
TL;DR: The compounds in Shufeng Jiedu Capsule can regulate the signaling pathway of human cytomegalov virus infection, Kaposi's sarcoma associated herpesvirus infection, IL-17 signaling pathway, small cell lung cancer, etc. to treat COVID-19 by binding with SARS-CoV-2 3CL hydrolase and ACE2.
Proceedings ArticleDOI
Drug Repurposing For SARS-COV-2 Using Molecular Docking
TL;DR: In this article , a leading drug candidate Cepharanthine (CEP) has shown better results and effectiveness than recently used antiviral drug candidates such as Favipiravir, IDX184, Remedesivir, Ribavirin and etc.
Proceedings ArticleDOI
Drug Repurposing For SARS-COV-2 Using Molecular Docking
TL;DR: Cepharanthine potential therapeutic importance as a drug of choice in managing COVID-19 cases is analyzed and it is anticipated that proposed study would be beneficial for researchers and medical practitioners in handling SARS-CoV-2 and its variant related diseases.
References
More filters
Journal ArticleDOI
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Chaolin Huang,Yeming Wang,Xingwang Li,Lili Ren,Jianping Zhao,Yi Hu,Li Zhang,Guohui Fan,Jiuyang Xu,Xiaoying Gu,Zhenshun Cheng,Ting Yu,Jia'an Xia,Yuan Wei,Wenjuan Wu,Xuelei Xie,Wen Yin,Li Hui,Min Liu,Yan Xiao,Hong Gao,Li Guo,Jungang Xie,Guang-Fa Wang,Rongmeng Jiang,Zhancheng Gao,Qi Jin,Jianwei Wang,Bin Cao +28 more
TL;DR: The epidemiological, clinical, laboratory, and radiological characteristics and treatment and clinical outcomes of patients with laboratory-confirmed 2019-nCoV infection in Wuhan, China, were reported.
Journal ArticleDOI
Clinical Characteristics of Coronavirus Disease 2019 in China.
Wei-jie Guan,Zhengyi Ni,Yu Hu,Wenhua Liang,Chun-Quan Ou,Jianxing He,Lei Liu,Hong Shan,Chunliang Lei,David S.C. Hui,Bin Du,Lanjuan Li,Guang Zeng,Kowk-Yung Yuen,Ruchong Chen,Chun-Li Tang,Tao Wang,Ping-Yan Chen,Jie Xiang,Shiyue Li,Jinlin Wang,Zi-jing Liang,Yi-xiang Peng,Li Wei,Yong Liu,Ya-hua Hu,Peng Peng,Jian-ming Wang,Ji-yang Liu,Zhong Chen,Gang Li,Zhi-jian Zheng,Shao-qin Qiu,Jie Luo,Chang-jiang Ye,Shao-yong Zhu,Nanshan Zhong +36 more
TL;DR: During the first 2 months of the current outbreak, Covid-19 spread rapidly throughout China and caused varying degrees of illness, and patients often presented without fever, and many did not have abnormal radiologic findings.
Journal ArticleDOI
Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.
Dawei Wang,Bo Hu,Chang Hu,Fangfang Zhu,Xing Liu,Jing Zhang,Binbin Wang,Hui Xiang,Zhenshun Cheng,Yong Xiong,Yan Zhao,Yirong Li,Xinghuan Wang,Zhiyong Peng +13 more
TL;DR: The epidemiological and clinical characteristics of novel coronavirus (2019-nCoV)-infected pneumonia in Wuhan, China, and hospital-associated transmission as the presumed mechanism of infection for affected health professionals and hospitalized patients are described.
Journal ArticleDOI
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
Markus Hoffmann,Hannah Kleine-Weber,Simon Schroeder,Nadine Krüger,Tanja Herrler,Sandra Erichsen,Tobias S. Schiergens,Georg Herrler,Nai Huei Wu,Andreas Nitsche,Marcel A. Müller,Christian Drosten,Christian Drosten,Stefan Pöhlmann +13 more
TL;DR: It is demonstrated that SARS-CoV-2 uses the SARS -CoV receptor ACE2 for entry and the serine protease TMPRSS2 for S protein priming, and it is shown that the sera from convalescent SARS patients cross-neutralized Sars-2-S-driven entry.
Journal ArticleDOI
Pathological findings of COVID-19 associated with acute respiratory distress syndrome.
Zhe Xu,Lei Shi,Yijin Wang,Ji-Yuan Zhang,Lei Huang,Chao Zhang,Shuhong Liu,Peng Zhao,Hongxia Liu,Li Zhu,Yanhong Tai,Changqing Bai,Tingting Gao,Jin-Wen Song,Peng Xia,Jing-Hui Dong,Jingmin Zhao,Fu-Sheng Wang +17 more
TL;DR: O surto do novo coronavÃrus (COVID-19) em Wuhan, China, iniciado em dezembro de 2019, evoluiu para se tornar uma pandemia global A.